CD3xHER2 bsAb‐Mediated Activation of Resting T‐cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFNγ and TNFα
European Journal of Immunology · 2025
DOI: 10.1002/eji.202451589 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Chen-Yi Liao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Antibodies, Bispecific, CD3 Complex, T-Lymphocytes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genmab BV, Dutch Research Council, NWO.
Abstract (Originalsprache)
Bispecific antibodies (bsAbs) bridging CD3 on T‐cells to tumor‐associated antigens (TAA) on tumor cells can direct T‐cell immunity to solid tumors. “Bystander killing”, where T‐cell targeting of TAA‐positive tumor cells also leads to the eradication of TAA‐negative cells, may overcome TAA heterogeneity. While bystander activity of activated, engineered T‐cells has been shown to be robust and wide‐reaching, spatiotemporal aspects of bsAb‐mediated bystander activity are unresolved. Here, we developed a model where breast cancer tumoroids varying in HER2 expression were printed in to extracellular matrix (ECM) scaffolds. We generated (1) mixed tumors containing different ratios of HER2 + and HER2 − tumor cells, and (2) HER2 + and HER2 − tumoroids spaced at different distances within the ECM scaffold. Subsequently, tumors were exposed to peripheral blood‐derived T‐cells in the presence of CD3xHER2 bsAbs. We find that CD3xHER2 bsAb‐mediated interaction of resting, nonactivated T‐cells with HER2 + tumor cells is sufficient (1) to eliminate 50% HER2 − cells in mixed tumor areas, and (2) to eradicate distant HER2 − tumor areas. Such bystander killing involves paracrine IFNγ and TNFα activity but does not require T‐cell accumulation in HER2 − areas. These findings indicate that bystander eradication of TAA‐negative cells can significantly contribute to bsAb therapy for solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
- Genmab B.V., Utrecht, the Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
ORCID-Profile: Chen-Yi Liao, Erik H J Danen
Förderung
- Genmab BV
- Dutch Research Council
- NWO
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Zitieren
APA
Liao, C. Y., Engelberts, P., van Dijk, M., Timmermans, A., Martens, J. W. M., Neubert, E., & Danen, E. H. J. (2025). CD3xHER2 bsAb‐Mediated Activation of Resting T‐cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFNγ and TNFα. European Journal of Immunology. https://doi.org/10.1002/eji.202451589
Vancouver
Liao CY, Engelberts P, van Dijk M, Timmermans A, Martens JWM, Neubert E, et al. CD3xHER2 bsAb‐Mediated Activation of Resting T‐cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFNγ and TNFα. European Journal of Immunology. 2025. doi:10.1002/eji.202451589
BibTeX
@article{Liao2025,
author = {Liao, Chen-Yi and Engelberts, Patrick and van Dijk, Michiel and Timmermans, Annemieke and Martens, John W M and Neubert, Elsa and Danen, Erik H J},
title = {CD3xHER2 bsAb‐Mediated Activation of Resting T‐cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFNγ and TNFα},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.202451589}
}
EUVIMED